Page last updated: 2024-08-23

raloxifene hydrochloride and risedronic acid

raloxifene hydrochloride has been researched along with risedronic acid in 56 studies

Research

Studies (56)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (1.79)	18.2507
2000's	44 (78.57)	29.6817
2010's	8 (14.29)	24.3611
2020's	3 (5.36)	2.80

Authors

Authors	Studies
Dunlop, MB; Lane, NE	1
Dijkmans, BA; Lems, WF	1
Baran, DT	1
Compston, JE	1
McClung, B; McClung, M	1
Kruse, HP	1
Välimäki, MJ	1
Baranauskaite, A; Savickiene, A	1
Begerow, B; Hinz, C; Minne, HW; Pfeifer, M; Pollähne, W	1
Bartl, R	2
Kessenich, C	1
Hatzigeorgiou, C; Jackson, JL; Tofferi, JK; Wei, GS	1
Zizic, TM	1
Keller, MI	1
Brecht, JG; Huppertz, E; Kruse, HP; Möhrke, W; Oestreich, A	1
Nakamura, T	1
Hosking, DJ; Pande, I	2
Brewer, N; Davis, S; De Nigris, E; Jones, ML; Oakley, J; Stevenson, M	1
Chesnut, CH; Gass, ML; Hamdy, RC; Holick, MF; Leib, ES; Lewiecki, ME; Maricic, M; Watts, NB	1
Takada, J	1
Hochberg, MC; Rizzoli, R	1
Boccuzzi, SJ; Downey, TW; Foltz, SH; Kahler, KH; Omar, MA	1
Adachi, J; Blackhouse, G; Goeree, R	1
Adami, S; Agnusdei, D; Gentilella, R; Iori, N; Isaia, G; Luisetto, G; Minisola, S; Nuti, R; Sinigaglia, L	1
Allen, MR; Burr, DB; Follet, H; Khurana, M; Sato, M	1
Fadillioglu, E; Kaya, H; Ozgocmen, S; Yilmaz, Z	1
Chen, SH; Chen, YJ; Hall, BJ; Khan, MA; Kung, AW; Mirasol, R; Pasion, EG; Shah, GA; Sivananthan, SK; Tam, F; Tay, BK; Thiebaud, D	1
Arnold, M; Avorn, J; Brookhart, MA; Finkelstein, JS; Katz, JN; Mogun, H; Patrick, AR; Polinski, JM; Solmon, DH	1
Akçay, A; Bavbek, N; Inegöl, I; Kanbay, M; Turgut, FH; Uz, E; Yanik, B; Yanik, T	1
Rizzoli, R	1
Christodoulakos, GE; Marín, F; Mellström, D; Nickelsen, T; Pavo, I; Petto, H; Ringe, JD	1
Allen, MR; Burr, DB; Delmas, PD; Gineyts, E; Leeming, DJ	1
Adami, S; Agnusdei, D; Gentilella, R; Isaia, G; Luisetto, G; Minisola, S; Nuti, R; Silvestri, S; Sinigaglia, L	1
Gärtner, R	1
Brookhart, MA; Cadarette, SM; Katz, JN; Solomon, DH; Stedman, MR; Stürmer, T	1
Adami, S; Bianchi, G; Di Munno, O; Fiore, CE; Giannini, S; Minisola, S; Rossini, M; Sinigaglia, L	1
Verhaar, HJ	1
Stepan, JJ; Zikan, V	1
Baytur, Y; Demir, BC; Gumuser, G; Inceboz, U; Ozbilgin, K; Uyar, Y	1
Glendenning, P; Inderjeeth, CA; Lee, S	1
Ferrari, S; Fujiwara, S; Hagino, H; Lange, JL; Nakamura, T; Watts, NB	1
Landfeldt, E; Lang, A; Robbins, S; Ström, O	1
El-Abd, EE; El-Ashmawy, NE; El-Bahrawy, HA; Haggag, AA; Khedr, NF	1
Ehlert, KM; Hernandez, CJ; Lin, I; Matheny, JB; Slyfield, CR; Tkachenko, EV; Tomlinson, RE; Wilson, DL	1
Gandhi, S; Modi, A; Sen, S; Siris, ES; Tang, J	1
Reid, IR	1
Barron, R; Durden, E; Juneau, P; Lopez-Gonzalez, L; Pinto, L	1
Deng, Y; Li, C; Li, L; Qu, Y; Wang, F	1
Chen, D; Huang, X; Jin, Z; Liu, Q; Ma, T; Ye, Z	1
Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T	1

Reviews

20 review(s) available for raloxifene hydrochloride and risedronic acid

Article	Year
Osteoporosis: diagnosis, prevention, and treatment of established disease. Bulletin on the rheumatic diseases, 1999, Volume: 48, Issue:6 Topics: Age Factors; Aged; Alendronate; Calcitonin; Calcium Channel Blockers; Calcium, Dietary; Dietary Supplements; Drug Therapy, Combination; Estrogens; Etidronic Acid; Exercise; Female; Hormone Replacement Therapy; Humans; Male; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Vitamin D	1999
[Effect of anti-osteoporosis agents on the incidence of vertebral fractures]. Nederlands tijdschrift voor geneeskunde, 2000, Oct-07, Volume: 144, Issue:41 Topics: Alendronate; Bone Density; Calcitonin; Calcium Channel Blockers; Densitometry; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Osteoporosis, Postmenopausal; Postmenopause; Radiography; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Injuries; Spine	2000
Osteoporosis: which current treatments reduce fracture risk? Cleveland Clinic journal of medicine, 2000, Volume: 67, Issue:10 Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Calcium Channel Blockers; Estrogen Replacement Therapy; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators	2000
Pharmacologic therapy for the treatment and prevention of osteoporosis. The Nursing clinics of North America, 2001, Volume: 36, Issue:3 Topics: Aged; Alendronate; Bone Density; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Patient Compliance; Patient Selection; Primary Prevention; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome	2001
[Osteoporosis]. Der Internist, 2002, Volume: 43, Issue:12 Topics: Alendronate; Bone Density; Drug Therapy, Combination; Estrogen Replacement Therapy; Etidronic Acid; Evidence-Based Medicine; Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid	2002
An approach to postmenopausal osteoporosis treatment: a case study review. Journal of the American Academy of Nurse Practitioners, 2003, Volume: 15, Issue:12 Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Exercise Therapy; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Smoking; Vitamin D	2003
Osteoporosis management in the new millennium. Primary care, 2003, Volume: 30, Issue:4 Topics: Alendronate; Bone Density; Calcitonin; Calcium; Estrogens; Etidronic Acid; Exercise; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid	2003
Pharmacologic prevention of osteoporotic fractures. American family physician, 2004, Oct-01, Volume: 70, Issue:7 Topics: Aged; Alendronate; Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators	2004
Treating osteoporosis in post-menopausal women: a case approach. Cleveland Clinic journal of medicine, 2004, Volume: 71, Issue:10 Topics: Aged; Alendronate; Densitometry; Diphosphonates; Etidronic Acid; Female; Humans; Mass Screening; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome	2004
[Bone quality in treatment with raroxifene ]. Clinical calcium, 2004, Volume: 14, Issue:5 Topics: Bone Density; Etidronic Acid; Evidence-Based Medicine; Femoral Neck Fractures; Humans; Meta-Analysis as Topic; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Regression Analysis; Reproducibility of Results; Risedronic Acid; Spinal Fractures; Testosterone	2004
Oral antiresorptive therapy. Current rheumatology reports, 2005, Volume: 7, Issue:1 Topics: Administration, Oral; Alendronate; Anabolic Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Fractures, Bone; Glucocorticoids; Humans; Ibandronic Acid; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide	2005
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health technology assessment (Winchester, England), 2005, Volume: 9, Issue:22 Topics: Age Factors; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Cost-Benefit Analysis; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Teriparatide	2005
Oral antiresorptive therapy. Current osteoporosis reports, 2004, Volume: 2, Issue:4 Topics: Administration, Oral; Aged; Alendronate; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Severity of Illness Index; Treatment Outcome	2004
Review of treatment modalities for postmenopausal osteoporosis. Southern medical journal, 2005, Volume: 98, Issue:10 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Combined Modality Therapy; Diet; Dietary Supplements; Diphosphonates; Etidronic Acid; Exercise; Female; Fish Oils; Hip Fractures; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Teriparatide; Vitamin D; Vitamin D Deficiency	2005
[Application of anti-resorptive drugs for the treatment of osteoporosis]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:2 Topics: Aged; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid	2006
Long-term experience with alendronate in the treatment of osteoporosis. Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:9 Topics: Aged; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcitonin; Drug Administration Schedule; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid	2006
[Osteoporosis in the elderly--diagnosis and treatment]. MMW Fortschritte der Medizin, 2005, Feb-17, Volume: 147, Issue:7 Topics: Accidental Falls; Age Factors; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium; Diphosphonates; Etidronic Acid; Exercise; Female; Hip Fractures; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Sex Factors; Spinal Fractures; Vitamin D	2005
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2011, Volume: 22, Issue:3 Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Patient Compliance; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Treatment Outcome	2011
Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis. Medicine, 2020, Oct-02, Volume: 99, Issue:40 Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Case-Control Studies; Collagen Type I; Creatinine; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Tartrate-Resistant Acid Phosphatase; Treatment Outcome; Vitamin D	2020
The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis. Calcified tissue international, 2023, Volume: 112, Issue:6 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome	2023

Trials

4 trial(s) available for raloxifene hydrochloride and risedronic acid

Article	Year
Effects of calcitonin, risedronate, and raloxifene on erythrocyte antioxidant enzyme activity, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis. Archives of medical research, 2007, Volume: 38, Issue:2 Topics: Adult; Aged; Antioxidants; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcitonin; Erythrocytes; Etidronic Acid; Female; Humans; Lipid Peroxidation; Malondialdehyde; Middle Aged; Nitric Oxide; Osteoporosis, Postmenopausal; Oxidative Stress; Oxidoreductases; Raloxifene Hydrochloride; Risedronic Acid	2007
Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women. Journal of bone and mineral metabolism, 2007, Volume: 25, Issue:2 Topics: Aged; Alendronate; Asian People; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction; Postmenopause; Raloxifene Hydrochloride; Risedronic Acid; Surveys and Questionnaires	2007
The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women. Renal failure, 2007, Volume: 29, Issue:4 Topics: Aged; Alendronate; Bone Density Conservation Agents; C-Reactive Protein; Calcium; Etidronic Acid; Female; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Osteoporosis, Postmenopausal; Phosphorus; Raloxifene Hydrochloride; Risedronic Acid; Uric Acid	2007
Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone. Bone, 2009, Volume: 44, Issue:4 Topics: Aged; Aged, 80 and over; Alendronate; Area Under Curve; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Chelating Agents; Collagen Type I; Edetic Acid; Etidronic Acid; Female; Humans; Hypocalcemia; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptides; Raloxifene Hydrochloride; Risedronic Acid	2009

Other Studies

32 other study(ies) available for raloxifene hydrochloride and risedronic acid

Article	Year
Drugs for prevention and treatment of postmenopausal osteoporosis. The Medical letter on drugs and therapeutics, 2000, Oct-16, Volume: 42, Issue:1090 Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Resorption; Breast Neoplasms; Calcitonin; Calcium; Calcium Channel Blockers; Clinical Trials as Topic; Densitometry; Dose-Response Relationship, Drug; Estrogens; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Vitamin D	2000
Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist? Bone, 2000, Volume: 27, Issue:6 Topics: Aged; Alendronate; Calcitriol; Calcium Channel Agonists; Calcium Channel Blockers; Estrogen Antagonists; Etidronic Acid; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Spinal Fractures	2000
[Economic aspects of osteoporosis therapy. What does a prevented fracture cost?]. MMW Fortschritte der Medizin, 2001, Nov-22, Volume: 143, Issue:47 Topics: Aged; Alendronate; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Spontaneous; Germany; Humans; National Health Programs; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Spinal Fractures	2001
[Patients with fractures are in the front line for osteoporosis treatment but how to treat?]. Duodecim; laaketieteellinen aikakauskirja, 2001, Volume: 117, Issue:24 Topics: Alendronate; Bone Density; Calcitonin; Etidronic Acid; Fractures, Bone; Health Services Accessibility; Humans; Osteoporosis; Physician's Role; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors	2001
[Osteoporosis: diagnosis, prevention and treatment]. Medicina (Kaunas, Lithuania), 2002, Volume: 38, Issue:2 Topics: Adult; Aged; Calcitonin; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Injections, Intramuscular; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators	2002
[Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate]. MMW Fortschritte der Medizin, 2002, Oct-31, Volume: 144, Issue:44 Topics: Activities of Daily Living; Age Factors; Alendronate; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Disabled Persons; Etidronic Acid; Female; Femoral Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Pain; Raloxifene Hydrochloride; Risedronic Acid; Sex Factors; Spinal Fractures	2002
Medications for postmenopausal osteoporosis prevention. Harvard women's health watch, 2002, Volume: 10, Issue:4 Topics: Alendronate; Bone Density; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators	2002
[Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?]. MMW Fortschritte der Medizin, 2004, May-20, Volume: 146, Issue:21 Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Etidronic Acid; Evidence-Based Medicine; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures	2004
Health-economic comparison of three recommended drugs for the treatment of osteoporosis. International journal of clinical pharmacology research, 2004, Volume: 24, Issue:1 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Cohort Studies; Cost-Benefit Analysis; Etidronic Acid; Female; Germany; Hip Fractures; Humans; Incidence; Insurance, Pharmaceutical Services; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid	2004
[Update 2004. Osteoporosis--management--current status]. Krankenpflege Journal, 2004, Volume: 42, Issue:7-10 Topics: Aged; Aged, 80 and over; Alendronate; Calcium, Dietary; Cross-Sectional Studies; Etidronic Acid; Female; Fractures, Spontaneous; Germany; Health Surveys; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risedronic Acid; Spinal Fractures; Vitamin D	2004
Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. Southern medical journal, 2006, Volume: 99, Issue:6 Topics: Aged; Alendronate; Bone Density Conservation Agents; Comorbidity; Etidronic Acid; Female; Humans; Male; Managed Care Programs; Middle Aged; Osteoporosis; Patient Compliance; Raloxifene Hydrochloride; Risedronic Acid	2006
Cost-effectiveness of alternative treatments for women with osteoporosis in Canada. Current medical research and opinion, 2006, Volume: 22, Issue:7 Topics: Aged; Alendronate; Bone Density Conservation Agents; Canada; Cost-Benefit Analysis; Decision Support Techniques; Etidronic Acid; Female; Humans; Markov Chains; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid	2006
Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2006, Volume: 21, Issue:10 Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Italy; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Risk Factors; Vitamin D	2006
Antiremodeling agents influence osteoblast activity differently in modeling and remodeling sites of canine rib. Calcified tissue international, 2006, Volume: 79, Issue:4 Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Matrix; Bone Remodeling; Dogs; Etidronic Acid; Female; Osteoblasts; Periosteum; Raloxifene Hydrochloride; Ribs; Risedronic Acid	2006
Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. The American journal of medicine, 2007, Volume: 120, Issue:3 Topics: Aged; Aged, 80 and over; Alendronate; Attitude to Health; Bone Density; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Cross-Over Studies; Drug Administration Schedule; Etidronic Acid; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Patient Compliance; Proportional Hazards Models; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Risk Assessment; Severity of Illness Index; Treatment Outcome; United States	2007
Osteoporosis: non-hormonal treatment. Climacteric : the journal of the International Menopause Society, 2007, Volume: 10 Suppl 2 Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Denosumab; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Thiophenes; Vitamin D; Women's Health	2007
Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women. Current medical research and opinion, 2007, Volume: 23, Issue:11 Topics: Alendronate; Drug Administration Schedule; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Patient Compliance; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Risedronic Acid	2007
Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2008, Volume: 19, Issue:3 Topics: Alendronate; Amino Acids; Animals; Arginine; Bone Density Conservation Agents; Bone Remodeling; Collagen; Diphosphonates; Dogs; Dose-Response Relationship, Drug; Etidronic Acid; Female; Lumbar Vertebrae; Lysine; Raloxifene Hydrochloride; Risedronic Acid	2008
Osteoporosis treatment and fracture incidence: the ICARO longitudinal study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2008, Volume: 19, Issue:8 Topics: Adult; Age Factors; Aged; Alendronate; Body Mass Index; Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Humans; Italy; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Treatment Failure	2008
Summaries for patients. Drug therapy for osteoporosis. Annals of internal medicine, 2008, May-06, Volume: 148, Issue:9 Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Male; New Jersey; Osteoporosis; Osteoporosis, Postmenopausal; Pennsylvania; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors	2008
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Annals of internal medicine, 2008, May-06, Volume: 148, Issue:9 Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Male; New Jersey; Osteoporosis; Osteoporosis, Postmenopausal; Pennsylvania; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors	2008
Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2009, Volume: 20, Issue:2 Topics: Activities of Daily Living; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; Confounding Factors, Epidemiologic; Dietary Supplements; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Logistic Models; Middle Aged; Odds Ratio; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Risk; Treatment Outcome; Vitamin D; Vitamin D Deficiency	2009
[Treatment of osteoporosis in the elderly: what is the evidence?]. Tijdschrift voor gerontologie en geriatrie, 2008, Volume: 39, Issue:5 Topics: Age Factors; Aged; Aged, 80 and over; Aging; Alendronate; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Teriparatide; Treatment Outcome	2008
Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats. Maturitas, 2009, Jul-20, Volume: 63, Issue:3 Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bone Density; Bone Density Conservation Agents; Clomiphene; Estrogens; Etidronic Acid; Female; Femur; Heptanoic Acids; Osteoporosis; Ovariectomy; Pyrroles; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Risedronic Acid; Selective Estrogen Receptor Modulators; Tibia	2009
Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study. Journal of bone and mineral metabolism, 2011, Volume: 29, Issue:5 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Case-Control Studies; Etidronic Acid; Female; Hip Fractures; Humans; Longitudinal Studies; Raloxifene Hydrochloride; Risedronic Acid	2011
Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA). Calcified tissue international, 2011, Volume: 89, Issue:3 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Etidronic Acid; Female; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Male; Medication Adherence; Middle Aged; Organometallic Compounds; Osteoporosis; Raloxifene Hydrochloride; Registries; Retrospective Studies; Risedronic Acid; Sweden; Thiophenes	2011
Modulation of bone turnover in orchidectomized rats treated with raloxifene and risedronate. Fundamental & clinical pharmacology, 2013, Volume: 27, Issue:5 Topics: Administration, Oral; Animals; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium; Cathepsin K; Cell Count; Drug Therapy, Combination; Etidronic Acid; Injections, Subcutaneous; Male; Orchiectomy; Osteoclasts; Osteocytes; Osteoporosis; Radiography; Raloxifene Hydrochloride; Random Allocation; Rats; Rats, Wistar; Risedronic Acid	2013
Anti-resorptive agents reduce the size of resorption cavities: a three-dimensional dynamic bone histomorphometry study. Bone, 2013, Volume: 57, Issue:1 Topics: Animals; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Etidronic Acid; Female; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Risedronic Acid	2013
Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis. Current medical research and opinion, 2014, Volume: 30, Issue:1 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Managed Care Programs; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Teriparatide; United States; Zoledronic Acid	2014
Efficacy, effectiveness and side effects of medications used to prevent fractures. Journal of internal medicine, 2015, Volume: 277, Issue:6 Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid	2015
Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Archives of osteoporosis, 2017, Volume: 12, Issue:1 Topics: Aged; Bone Density Conservation Agents; Denosumab; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Logistic Models; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Postmenopause; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; United States; Zoledronic Acid	2017
Efficacy of combined medication of risedronate sodium and selective estrogen receptor modulator on the postmenopausal osteoporosis. Pakistan journal of pharmaceutical sciences, 2020, Volume: 33, Issue:1(Special) Topics: Aged; Bone and Bones; Bone Density; Drug Therapy, Combination; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators	2020